These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 30256689)
1. A case study where pharmaceutical salts were used to address the issue of low in vivo exposure. Sigfridsson K; Ulvinge ML; Svensson L; Granath AK Drug Dev Ind Pharm; 2019 Feb; 45(2):202-211. PubMed ID: 30256689 [TBL] [Abstract][Full Text] [Related]
2. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611 [TBL] [Abstract][Full Text] [Related]
3. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats. Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980 [TBL] [Abstract][Full Text] [Related]
4. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
5. Biopharmaceutic Profiling of Salts to Improve Absorption of Poorly Soluble Basic Drugs. Tannergren C; Karlsson E; Sigfridsson K; Lindfors L; Ku A; Polentarutti B; Carlert S J Pharm Sci; 2016 Nov; 105(11):3314-3323. PubMed ID: 27637320 [TBL] [Abstract][Full Text] [Related]
6. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations. Williams HD; Ford L; Han S; Tangso KJ; Lim S; Shackleford DM; Vodak DT; Benameur H; Pouton CW; Scammells PJ; Porter CJH Mol Pharm; 2018 Dec; 15(12):5678-5696. PubMed ID: 30376336 [TBL] [Abstract][Full Text] [Related]
7. Salt Disproportionation in the Solid State: Role of Solubility and Counterion Volatility. Thakral NK; Behme RJ; Aburub A; Peterson JA; Woods TA; Diseroad BA; Suryanarayanan R; Stephenson GA Mol Pharm; 2016 Dec; 13(12):4141-4151. PubMed ID: 27766882 [TBL] [Abstract][Full Text] [Related]
8. The Selection of a Pharmaceutical Salt-The Effect of the Acidity of the Counterion on Its Solubility and Potential Biopharmaceutical Performance. He Y; Orton E; Yang D J Pharm Sci; 2018 Jan; 107(1):419-425. PubMed ID: 29107790 [TBL] [Abstract][Full Text] [Related]
9. Preformulation investigation and challenges; salt formation, salt disproportionation and hepatic recirculation. Sigfridsson K; Nilsson L; Ahlqvist M; Andersson T; Granath AK Eur J Pharm Sci; 2017 Jun; 104():262-272. PubMed ID: 28366653 [TBL] [Abstract][Full Text] [Related]
10. State of the Art of Pharmaceutical Solid Forms: from Crystal Property Issues to Nanocrystals Formulation. Couillaud BM; Espeau P; Mignet N; Corvis Y ChemMedChem; 2019 Jan; 14(1):8-23. PubMed ID: 30457705 [TBL] [Abstract][Full Text] [Related]
11. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility. Elder DP; Holm R; Diego HL Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973 [TBL] [Abstract][Full Text] [Related]
12. Salt formation to improve drug solubility. Serajuddin AT Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064 [TBL] [Abstract][Full Text] [Related]
13. Estimating the maximal solubility advantage of drug salts. Skrdla PJ Int J Pharm; 2021 Feb; 595():120228. PubMed ID: 33484924 [TBL] [Abstract][Full Text] [Related]
14. Practical method for preparing nanosuspension formulations for toxicology studies in the discovery stage: formulation optimization and in vitro/in vivo evaluation of nanosized poorly water-soluble compounds. Komasaka T; Fujimura H; Tagawa T; Sugiyama A; Kitano Y Chem Pharm Bull (Tokyo); 2014; 62(11):1073-82. PubMed ID: 25366311 [TBL] [Abstract][Full Text] [Related]
15. Salt formation improved the properties of a candidate drug during early formulation development. Sigfridsson K; Ahlqvist M; Lindsjö M; Paulsson S Eur J Pharm Sci; 2018 Jul; 120():162-171. PubMed ID: 29730322 [TBL] [Abstract][Full Text] [Related]
16. A preformulation evaluation of a photosensitive surface active compound, explaining concentration dependent degradation. Sigfridsson K; Carlsson KE Eur J Pharm Sci; 2017 Nov; 109():650-656. PubMed ID: 28736127 [TBL] [Abstract][Full Text] [Related]
17. Measurement and Accurate Interpretation of the Solubility of Pharmaceutical Salts. He Y; Ho C; Yang D; Chen J; Orton E J Pharm Sci; 2017 May; 106(5):1190-1196. PubMed ID: 28153596 [TBL] [Abstract][Full Text] [Related]
18. Salt disproportionation: A material science perspective. Thakral NK; Kelly RC Int J Pharm; 2017 Mar; 520(1-2):228-240. PubMed ID: 28163222 [TBL] [Abstract][Full Text] [Related]
19. Synthon Approach in Crystal Engineering to Modulate Physicochemical Properties in Organic Salts of Chlorpropamide. Menon AM; Sidhartha NN; Shruti I; Suresh A; Meena R; Dikundwar AG; Chopra D Mol Pharm; 2024 Jun; 21(6):2894-2907. PubMed ID: 38688017 [TBL] [Abstract][Full Text] [Related]
20. An Examination of Water Vapor Sorption by Multicomponent Crystalline and Amorphous Solids and Its Effects on Their Solid-State Properties. Newman A; Zografi G J Pharm Sci; 2019 Mar; 108(3):1061-1080. PubMed ID: 30391302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]